Du_2023_Eur.J.Nucl.Med.Mol.Imaging__

Reference

Title : [(18)F]FNDP PET neuroimaging test-retest repeatability and whole-body dosimetry in humans - Du_2023_Eur.J.Nucl.Med.Mol.Imaging__
Author(s) : Du Y , Coughlin JM , Amindarolzarbi A , Sweeney SE , Harrington CK , Brosnan MK , Zandi A , Shinehouse LK , Sanchez ANR , Abdallah R , Holt DP , Fan H , Lesniak WG , Nandi A , Rowe SP , Solnes LB , Dannals RF , Horti AG , Lodge MA , Pomper MG
Ref : Eur J Nucl Med Mol Imaging , : , 2023
Abstract :

PURPOSE: Soluble epoxide hydrolase (sEH) is an enzyme that shapes immune signaling through its role in maintaining the homeostasis of polyunsaturated fatty acids and their related byproducts. [(18)F]FNDP is a radiotracer developed for use with positron emission tomography (PET) to image sEH, which has been applied to imaging sEH in the brains of healthy individuals. Here, we report the test-retest repeatability of [(18)F]FNDP brain PET binding and [(18)F]FNDP whole-body dosimetry in healthy individuals. METHODS: Seven healthy adults (4 men, 3 women, ages 40.1 +/- 4.6 years) completed [(18)F]FNDP brain PET on two occasions within a period of 14 days in a test-retest study design. [(18)F]FNDP regional total distribution volume (V(T)) values were derived from modeling time-activity data with a metabolite-corrected arterial input function. Test-retest variability, mean absolute deviation, and intraclass correlation coefficient (ICC) were investigated. Six other healthy adults (3 men, 3 women, ages 46.0 +/- 7.0 years) underwent [(18)F]FNDP PET/CT for whole-body dosimetry, which was acquired over 4.5 h, starting immediately after radiotracer administration. Organ-absorbed doses and the effective dose were then estimated. RESULTS: The mean test-retest difference in regional V(T) (deltaV(T)) was 0.82 +/- 5.17%. The mean absolute difference in regional V(T) was 4.01 +/- 3.33%. The ICC across different brain regions ranged from 0.92 to 0.99. The organs with the greatest radiation-absorbed doses included the gallbladder (0.081 +/- 0.024 mSv/MBq), followed by liver (0.077 +/- 0.018 mSv/MBq) and kidneys (0.063 +/- 0.006 mSv/MBq). The effective dose was 0.020 +/- 0.003 mSv/MBq. CONCLUSION: These data support a favorable test-retest repeatability of [(18)F]FNDP brain PET regional V(T). The radiation dose to humans from each [(18)F]FNDP PET scan is similar to that of other (18)F-based PET radiotracers.

PubMedSearch : Du_2023_Eur.J.Nucl.Med.Mol.Imaging__
PubMedID: 37458759

Related information

Inhibitor FNDP

Citations formats

Du Y, Coughlin JM, Amindarolzarbi A, Sweeney SE, Harrington CK, Brosnan MK, Zandi A, Shinehouse LK, Sanchez ANR, Abdallah R, Holt DP, Fan H, Lesniak WG, Nandi A, Rowe SP, Solnes LB, Dannals RF, Horti AG, Lodge MA, Pomper MG (2023)
[(18)F]FNDP PET neuroimaging test-retest repeatability and whole-body dosimetry in humans
Eur J Nucl Med Mol Imaging :

Du Y, Coughlin JM, Amindarolzarbi A, Sweeney SE, Harrington CK, Brosnan MK, Zandi A, Shinehouse LK, Sanchez ANR, Abdallah R, Holt DP, Fan H, Lesniak WG, Nandi A, Rowe SP, Solnes LB, Dannals RF, Horti AG, Lodge MA, Pomper MG (2023)
Eur J Nucl Med Mol Imaging :